New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
08:24 EDTKERXKeryx price target raised to $25 from $16 at Maxim
Maxim raised its price target for Keryx shares to $25 on expectations the company is now positioned to launch Zerenex by itself or with a partner following its capital raise. The firm keeps a Buy rating on the stock.
News For KERX From The Last 14 Days
Check below for free stories on KERX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 11, 2014
11:07 EDTKERXOptions with decreasing implied volatility
Subscribe for More Information
09:57 EDTKERXSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
September 10, 2014
11:22 EDTKERXOptions with decreasing implied volatility
Subscribe for More Information
September 9, 2014
12:02 EDTKERXOptions with decreasing implied volatility
Options with decreasing implied volatility: KERX CIEN FNSR PAY BKS PVH NAV BYI FTR JOY
September 8, 2014
16:18 EDTKERXOn The Fly: Closing Wrap
Subscribe for More Information
10:42 EDTKERXOptions with decreasing implied volatility
Options with decreasing implied volatility: KERX CONN CIEN INSM FNSR PAY PVH SWY
10:06 EDTKERXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:29 EDTKERXKeryx downgraded to Underperform from Market Perform at FBR Capital
Subscribe for More Information
09:18 EDTKERXKeryx price target raised to $32 from $30 at Roth Capital
Subscribe for More Information
09:12 EDTKERXOn The Fly: Pre-market Movers
Subscribe for More Information
07:38 EDTKERXKeryx label for ferric citrate incrementally negative, says JPMorgan
JPMorgan says the approved label for Keryx's ferric citrate is incrementally negative given the lack of clear articulation of ESA/IV iron sparing data. The firm keeps an Overweight rating on the stock with a $24 price target, saying Keryx's 2024 patents are strong.
06:26 EDTKERXKeryx downgraded to Underperform from Market Perform at FBR Capital

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use